Position:Home> News> Our News


Baheal Pharma's Nifedipine Controlled Release Tablets Approved by NMPA

On April 29, Qingdao Baheal Pharmaceutical Co. Ltd. (hereinafter referred to as "Baheal Pharma"), a subsidiary of Baheal Pharmaceutical Group, announced that the company's self-developed nifedipine controlled-release tablets ha...


Baheal Receives Four Honors at China Future Healthcare Rankings Top 100

On April 16, the "Future Healthcare 100" list was announced at the 5th Future Healthcare 100 Conference. Baheal Intelligent Technology, Easy Referral and Suzhou CHBiomedical, which are incubated by Baheal Investment, a subsidia...


Baheal Medical Partnered With Kawin in Liver Disease

On April 9, Qingdao Baheal Medical Inc. ("Baheal Medical")signed a strategic cooperation agreement with Beijing Kawin Technology Share-Holding Co., Ltd. (“Kawin”) . As a professional pharmaceutical brand commercialization platf...


Baheal Health City Complex Made Substantial Progress in Construction

On April 11, Baheal International Health City Living Room celebrated the topping out of the first Health City Complex in China. As the first start-up area of Baheal Health City Complex, Baheal International Health City Living R...


Baheal Medical Partnered With CSL Behring Again to Develop New Products

On March 30, CSL Behring, a global leader in biotherapeutics, announced at the CSL Behring Blood Products Retail Summit that it has partnered with Qingdao Baheal Medical Co. Ltd. ("Baheal Medical"). The two companies will work ...


Baheal Medical Partnered With Roche China For Oncology Products

On March 29, Roche China and Qingdao Baheal Medical Co. Ltd. ("Baheal Medical") announced partnership in oncology field. Roche has granted the marketing rights of its two major oncology products, Xeloda® (capecitabine tablets) ...


12345...19 Items